Homepage
Healthcare · Biotechnology · United States · Updated May 11, 1:54pm
$19.85
Price
$224.2M
Market Cap
23
Employees
0.79
Beta
Garry A. Neil
CEO
Business Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Business History
Price Overview
Last updated: May 11, 2026 1:54pm (just now)$19.85
-1.72 (-7.98%)
Day Range
$19.83 – $22.02
52-Week Range
$3.39 – $24.27
50-Day MA
$15.54
200-Day MA
$14.57
Volume
1,783,068.33
Analyst Price Targets
Low
$39.00
Consensus
$51.00
High
$60.00
(8 analysts)
Share Structure
Outstanding
11,294,117.00
Float
10,838,129.00
Free Float
96.0%
High free float
— 96.0% of shares trade freely, ~4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.40
Stock Price: $19.85
EPS (Diluted): -5.84
EPS (Diluted): -5.84
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.93
Stock Price: $19.85
Total Equity: $83.05M
Shares: 13,404,830
Total Equity: $83.05M
Shares: 13,404,830
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.51
Market Cap: $224.17M
Total Debt: $2.00M
Cash: $15.86M
EBITDA: -$72.93M
Total Debt: $2.00M
Cash: $15.86M
EBITDA: -$72.93M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$230.0M
Market Cap: $224.17M
Total Debt: $2.00M
Cash: $15.86M
Total Debt: $2.00M
Cash: $15.86M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-483.1%
Gross Profit: -$285,000
Revenue: $59,000
Revenue: $59,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-123,601.7%
Operating Income: -$72.93M
Revenue: $59,000
Revenue: $59,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-132,642.4%
Net Income: -$78.26M
Revenue: $59,000
Revenue: $59,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-77.9%
Net Income: -$78.26M
Total Equity: $83.05M
Total Equity: $83.05M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-70.2%
Operating Income: -$72.93M
Tax Rate: -0.2%
Equity: $83.05M
Total Debt: $2.00M
Cash: $15.86M
Tax Rate: -0.2%
Equity: $83.05M
Total Debt: $2.00M
Cash: $15.86M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
8.14
Current Assets: $105.29M
Current Liabilities: $12.94M
Current Liabilities: $12.94M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.02
Short-Term Debt: $0.00
Long-Term Debt: $2.00M
Total Debt: $2.00M
Total Equity: $83.05M
Long-Term Debt: $2.00M
Total Debt: $2.00M
Total Equity: $83.05M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.00
Revenue: $59,000
Shares: 13,404,830
Shares: 13,404,830
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$6.20
Total Equity: $83.05M
Shares: 13,404,830
Shares: 13,404,830
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.84
Operating CF: -$51.46M
CapEx: $0.00
Shares: 13,404,830
CapEx: $0.00
Shares: 13,404,830
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $19.85
Stock Price: $19.85
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$78.26M
Net Income: -$78.26M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AVTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Cost of Revenue | $1.5M | $3.4M | $1.3M | $-366,000 | $344,000 |
| Gross Profit | $3.9M | $14.6M | $640,000 | $807,000 | $-285,000 |
| Operating Expenses | $86.0M | $52.1M | $28.0M | $69.3M | $73.0M |
| Operating Income | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Net Income | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| EBITDA | -$80.5M | -$37.3M | -$23.3M | -$68.3M | -$72.9M |
| EPS | $-2,330.66 | $-1,062.65 | $-113.58 | $-4.32 | $-5.84 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $54.6M | $13.2M | $7.4M | $134.5M | $15.9M |
| Total Current Assets | $61.8M | $16.4M | $8.4M | $138.9M | $105.3M |
| Total Assets | $80.2M | $33.4M | $21.0M | $150.7M | $116.5M |
| Current Liabilities | $19.9M | $22.1M | $4.6M | $7.0M | $12.9M |
| Long-Term Debt | $32.8M | $13.5M | $0 | $0 | $2.0M |
| Total Liabilities | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Total Equity | $23.1M | -$10.9M | $7.3M | $133.0M | $83.0M |
| Retained Earnings | -$262.2M | -$303.8M | -$335.1M | -$370.3M | -$448.5M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Capital Expenditure | $-113,000 | $-95,000 | $-158,000 | $0 | $0 |
| Free Cash Flow | -$71.0M | -$26.8M | -$30.8M | -$49.1M | -$51.5M |
| Acquisitions (net) | $0 | $0 | $0 | $356,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.8M | -$41.4M | -$5.8M | $127.1M | -$118.6M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.0M $1.0M – $1.0M
|
$13,884 $13,884 – $13,884
|
$11.1M $11.1M – $11.1M
|
$120.3M $120.3M – $120.3M
|
| EBITDA |
-$1.0M -$1.0M – -$1.0M
|
$-13,884 $-13,884 – $-13,884
|
-$11.1M -$11.1M – -$11.1M
|
-$120.3M -$120.3M – -$120.3M
|
| Net Income |
-$57.3M -$90.1M – -$24.5M
|
-$51.6M -$80.2M – -$23.0M
|
-$45.8M -$45.8M – -$45.8M
|
-$24.4M -$24.4M – -$24.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +234.4% | -89.3% | -77.1% | -86.6% |
| Gross Profit Growth | +274.1% | -95.6% | +26.1% | -135.3% |
| Operating Income Growth | +54.4% | +26.9% | -150.5% | -6.4% |
| Net Income Growth | +50.6% | +24.3% | -11.4% | -122.8% |
| EBITDA Growth | +53.7% | +37.5% | -193.5% | -6.7% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-06 | VARKI PAUL | M-Exempt | 62,500.00 | $13.43 | $839,375 |
| 2026-05-06 | VARKI PAUL | M-Exempt | 12,563.00 | $8.04 | $101,007 |
| 2026-05-06 | VARKI PAUL | M-Exempt | 12,563.00 | $8.04 | $101,007 |
| 2026-05-06 | VARKI PAUL | M-Exempt | 62,500.00 | $13.43 | $839,375 |
| 2026-05-06 | VARKI PAUL | S-Sale | 37,375.00 | $18.91 | $706,836 |
| 2026-05-06 | VARKI PAUL | S-Sale | 5,196.00 | $19.78 | $102,783 |
| 2026-05-06 | VARKI PAUL | S-Sale | 22,839.00 | $21.22 | $484,541 |
| 2026-05-06 | VARKI PAUL | S-Sale | 9,253.00 | $22.70 | $210,029 |
| 2026-05-06 | VARKI PAUL | S-Sale | 400.00 | $23.71 | $9,484 |
| 2026-05-06 | Sullivan Christopher Ryan | M-Exempt | 47,000.00 | $8.04 | $377,880 |
| 2026-05-06 | Sullivan Christopher Ryan | M-Exempt | 47,000.00 | $8.04 | $377,880 |
| 2026-05-06 | Sullivan Christopher Ryan | S-Sale | 13,834.00 | $18.55 | $256,655 |
| 2026-05-06 | Sullivan Christopher Ryan | S-Sale | 12,347.00 | $19.28 | $238,093 |
| 2026-05-06 | Sullivan Christopher Ryan | S-Sale | 2,700.00 | $20.76 | $56,052 |
| 2026-05-06 | Sullivan Christopher Ryan | S-Sale | 9,219.00 | $21.37 | $197,008 |
| 2026-05-06 | Sullivan Christopher Ryan | S-Sale | 8,900.00 | $22.57 | $200,913 |
| 2026-05-05 | Doyle Mittie | M-Exempt | 1,000.00 | $12.65 | $12,650 |
| 2026-05-05 | Doyle Mittie | M-Exempt | 679.00 | $8.04 | $5,459 |
| 2026-05-06 | Doyle Mittie | M-Exempt | 77,905.00 | $12.65 | $985,498 |
| 2026-05-06 | Doyle Mittie | M-Exempt | 28,650.00 | $8.04 | $230,346 |
No community reviews yet for AVTX.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27